Introduction
============

Noonan syndrome (NS) is an autosomal dominant disorder with an estimated incidence of 1:1,000 to 1:2,500 live births[@B1]. It is characterized by short stature, distinctive facial appearance, congenital heart defects (most frequently pulmonary valve stenosis or hypertrophic cardiomyopathy), thoracic deformities, bleeding diathesis, and cryptorchidism[@B2].

Tartaglia et al.[@B3] demonstrated that the causative gene of NS is *PTPN11* on chromosome 12q24.1, encoding the protein tyrosine phosphatase, SHP-2, in 40% to 50% of cases. The other common causative genes of NS are *SOS1* (17%--28%) and *RAF1* (5%--17%)[@B4][@B5][@B6][@B7][@B8]. Genes accounting for less than 5% of NS are *KRAS*, *NRAS*, and *BRAF*[@B8][@B9]. Other rare causes of NS are *MEK1* and *RIT1* mutations[@B9][@B10]. Mutations in the *SHOC2* and *CBL* genes were reported in Noonan-like syndrome with loose anagen hair (NS/LAH)[@B7][@B11].

NS is a genetically heterogeneous disorder caused by up-regulated RAS-MAPK signaling, resulting in growth disturbances[@B4]. The RAS-MAPK cascade is activated in response to cytokines, hormones, and growth factors, and is a major mediator of early and late developmental processes, including morphology determination, organogenesis, synaptic plasticity processes, and growth[@B5]. SHP-2, a protein tyrosine kinase encoded by *PTPN11*, plays diverse roles in signal transduction via the RAS-MAPK pathway, such as growth hormone (GH) receptor signaling in children with NS[@B12]. Thus, short stature with delayed bone age is the most common clinical feature of NS[@B13], with a mean adult height below --2 SDS[@B14]. Over the last 2 decades, recombinant human GH (rhGH) treatment has been reported to increase height SDS in NS patients without severe adverse events[@B15]. Long-term rhGH therapy for about 4.2--11.8 years in NS has been reported to produce height gains varying from 0.6 to 2.0 SDS[@B16][@B17].

Our group previously reported that 1 year of rhGH therapy significantly improved height SDS in NS patients and the response to rhGH therapy was not affected by *PTPN11* mutations[@B18]. However, the long-term efficacy and safety of rhGH therapy in NS patients has remained elusive. Thus, this study evaluated the effects of long-term treatment with rhGH in NS patients and the influence of mutations in RAS-MAPK pathway genes.

Materials and methods
=====================

1. Subjects
-----------

This study included 11 males and 4 females with NS who received rhGH therapy for at least 3 years. Mean duration of rhGH therapy was 4.9 years (range, 3.3--6.6 years). The diagnosis of NS was based on the van der Burgt criteria[@B19]. Baseline characteristics of the 15 subjects are shown in [Table 1](#T1){ref-type="table"}. Among the 15 children, 12 had congenital heart defects, including pulmonic stenosis (7 subjects, 46.7%), ventricular septal defect (3 subjects, 20%), patent ductus arteriosus (4 subjects, 26.7%), atrial septal defect (2 subjects, 13.3%), or right ventricular defect (1 subject, 6.7%). Five of them had two or more congenital heart defects. Mutations in the *PTPN11* gene were identified in 9 subjects (60%). Mutations in *SOS1* were identified in 2 children (13.3%) and *KRAS* mutation in 1 child (6.7%) ([Table 1](#T1){ref-type="table"}). No mutations were identified in 3 of the subjects (20%).

2. Methods
----------

The rhGH (Norditropin; Novo Nordisk Pharma, Hellerup, Denmark) was administered at a dose of 50--75 µg/kg/day for 6 days a week subcutaneously. The main outcome measures were height SDS, growth velocity (GV), bone age, serum insulin-like growth factor 1 (IGF-1) SDS, and IGF binding protein 3 (IGFBP-3) SDS. The subjects\' height and weight were measured at baseline and every 6 months. Height and weight were expressed as SDS based on normative data from Korean references[@B20]. The complete blood count, routine chemistry, free T4, thyroid-stimulating hormone, IGF-1, and IGFBP-3 levels were measured at baseline and at 6-month intervals. IGF-1 SDS and IGFBP-3 SDS were calculated based on normative data from the Korean reference[@B21]. The subjects\' bone age was determined annually using the Greulich-Pyle method[@B22]. Electrocardiogram and echocardiogram were carried out every 6 months.

Puregene DNA isolation kits (Gentra, Minneapolis, MN, USA) were used for genomic DNA extraction from peripheral blood leukocytes. The coding regions and intronic flanking regions of the *PTPN11* (whole exons), *SOS1* (whole exons), *KRAS* (exons 1 and 4), *RAF1* (exons 7, 14, and 17), *SHOC2* (exon 1), *NRAS* (exon 3), *BRAF* (exons 6, 11, and 16), and *MEK1* (exon 3) genes were amplified by polymerase chain reaction with specific primers and directly sequenced using an ABI3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

3. Statistical analysis
-----------------------

The Friedman test was used to evaluate the effect of rhGH therapy. The Wilcoxon signed rank test was used to compare the changes between pre- and post-rhGH therapy. The relationships between genotypes of subjects and growth parameters, such as bone age, height SDS, GV, and serum IGF-1 and IGFBP-3 levels were assessed by the Mann-Whitney U-test. Statistical analyses were conducted using IBM SPSS Statistics ver. 21.0 (IBM Co., Armonk, NY, USA). *P*\<0.05 was considered statistically significant.

Results
=======

1. Efficacy of rhGH therapy in children with NS
-----------------------------------------------

The mean age at the start of treatment was 7.97±1.81 years (range, 5.7 to 11.3 years). Height SDS, GV, and serum IGF-1 SDS levels were significantly increased after rhGH therapy ([Table 2](#T2){ref-type="table"}). Height SDS increased from --2.64±0.64, to --1.54±1.24, to --2.13±1.08, respectively, at the first, second, and third years of treatment (*P*=0.005, *P*=0.003, and *P*=0.001, respectively). GV during the first year of treatment was highest (8.57±1.49 cm/yr). GV increased from 4.64±0.80 cm/yr at baseline to 6.79±1.26 and 6.41±1.54 cm/yr at the second and third years (*P*=0.001 and *P*=0.003, respectively). Serum IGF-1 SDS significantly increased from --1.28±1.03 to --0.10±0.94 after 3 years (*P*\<0.001). Serum IGFBP-3 SDS changed from --0.15±0.40 to --0.09±0.34, which was not statistically significant (*P*=0.074). Bone age increased from 5.09±2.12 years to 9.42±2.15 years after 3 years (*P*\<0.001). The bone age/chronologic age ratio increased from 0.62±0.13 at the start of treatment to 0.68±0.15, 0.79±0.1, and 0.86±0.1, respectively, after 1, 2, and 3 years of treatment and the end of treatment (*P*=0.02, *P*=0.001, and *P*=0.001, respectively). During treatment, there were no serious adverse events including the cardiac dysfunction, hypertrophic cardiomyopathy, malignancy, hyperglycemia, or thrombocytopenia with bleeding tendency.

2. Response to rhGH therapy according to genotypes
--------------------------------------------------

The influence of genotype was analyzed by comparing the growth parameters at the start of treatment and 1 year, 2 years, and 3 years after treatment. IGF-1 SDS was significantly different between the group with *PTPN11* mutations and the group without *PTPN11* mutations at the start of treatment (*P*=0.036). The other baseline data, including bone age, height SDS, GV, and serum IGFBP-3 levels, were not significantly different between the 2 groups (*P*=0.607, *P*=0.181, *P*=0.818, and *P*=0.224, respectively) ([Fig. 1](#F1){ref-type="fig"}). Responses to treatment over 3 years, represented by changes in bone age, GV, serum IGF-1 SDS, and IGFBP-3 SDS, were not significantly different among children with and without mutations in PTPN11 (*P*=0.755, *P*=0.864, *P*=0.113, and *P*=0.145, respectively). However, height SDS was significantly increased in patients without PTPN11 mutations compared to those with mutations (*P*=0.012) ([Fig. 1](#F1){ref-type="fig"}).

Discussion
==========

This paper demonstrated a significant increase in growth parameters, including bone age, height SDS, and IGF-1 SDS in children with NS after 3 years of rhGH therapy. In a previous study with 30 subjects, rhGH therapy increased GV by 2 cm/yr or more in 80% of the children after 12 months of rhGH therapy[@B23]. Long-term rhGH therapy for 3 years significantly increased height SDS from --2.7±0.40 to --1.9±0.9 in 23 NS children (*P*\<0.001) compared to 8 untreated patients[@B24]. However, GV acceleration was not significant during the second and third years (*P*=0.4 and *P*=0.5, respectively)[@B24].

Several studies have reported the association between *PTPN11* mutation and GH resistance by a postreceptor signaling defect[@B25][@B26]. The GH resistance in NS children with *PTPN11* mutations may contribute to short stature and their relatively poor response to rhGH[@B25]. Mean GH levels showed a tendency to be higher in the *PTPN11* mutation-positive group (*P*=0.075)[@B25]. However, IGF-1 and IGFBP-3 SDS levels were significantly lower in the PTPN11 mutation-positive group than in the *PTPN11* mutation-negative group (*P*=0.006)[@B25]. The improvement of height SDS after 1 year of rhGH therapy was significantly lower in the *PTPN11* mutation-positive group (*P*=0.007)[@B25]. In a prospective multicenter study in 35 NS patients, rhGH therapy for 2 years resulted in increased height SDS, which was significantly lower in the *PTPN11* mutationpositive group than the *PTPN11* mutation-negative group (*P*=0.03)[@B26]. Those findings were consistent with a recent study with an animal model showing reduced sensitivity to GH in *PTPN11*-mutated mice[@B27]. In contrast, the response of height SDS to GH treatment for 3.0--10.3 years was not significantly different between patients with or without *PTPN11* mutations (*P*=0.98)[@B16]. In the present study, there was a significant difference in height SDS between children with and without *PTPN11* mutations after 1, 2 and 3 years of rhGH therapy. GV was significantly different between 2 groups after 1 and 2 years of rhGH therapy. However, GV at third year was not significantly different between 2 groups, suggesting growth response was blunted after long-term rhGH therapy.

Cardiac anomaly is one of the most important characteristics of NS[@B2]. As pulmonary valve stenosis (30%--39%) and hypertrophic cardiomyopathy (9.5%--30%) are frequent problems in NS patients, careful monitoring is recommended to detect hypertrophic cardiomyopathy and progression of the underlying heart disease during the period of rhGH treatment[@B28][@B29]. From prospective rhGH trials over 3 years, no children with NS experienced any heart problems based on echocardiography[@B17][@B30]. Two patients have been reported to have mild progression of pulmonary valve stenosis, which was considered to be unrelated to rhGH therapy[@B16]. There were no cardiac complications during rhGH therapy in the current study.

In conclusion, long-term rhGH therapy in NS patients was safe and effective at improving height SDS, GV, and serum IGF-1 levels in accordance with previous studies. However, the meticulous monitoring of potential adverse events is still needed because of high dose of rhGH and preexisting hyperactivity of RAS-MAPK pathway. Height SDS in patients without *PTPN11*mutation was significantly increased compared to those with *PTPN11* mutation after 3 years of rhGH therapy.
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![Sequential changes of height SDS (A), GV (B), and IGF-1 SDS (C) during rhGH treatment in patients with Noonan syndrome with or without PTPN11 mutations. Mann-Whitney U-test was used to compare the response to rhGH therapy according to genotypes. P-values less than 0.05 were considered to be statistically significant. SDS, standard deviation score; GV, growth velocity; IGF-1, insulin-like growth factor 1; rhGH, recombinant human growth hormone.](apem-21-26-g001){#F1}

###### Clinical and endocrinological characteristics of patients with NS at baseline
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  No.   Sex   Age (yr)   MPH (cm)   Height SDS   Weight SDS   Growth velocity (cm/yr)   IGF-1 SDS   IGFBP-3 SDS   Heart anomaly      Molecular analysis   Initial dose of rhGH\
                                                                                                                                                          (µg/kg/day)
  ----- ----- ---------- ---------- ------------ ------------ ------------------------- ----------- ------------- ------------------ -------------------- -----------------------
  1     M     9.9        173        --3.61       --2.68       5                         --2.80      --0.55        VSD, PS            PTPN11 p.F285S       69

  2     M     6.2        170        --3.17       --2.17       6                         --1.57      --0.13        PS, ASD, RVH       PTPN11 p.N308S       62

  3     M     8.9        169        --2.79       --2.22       4                         --3.13      --0.49        PDA                PTPN11 p.N308D       63

  4     M     6.1        176        --2.69       --4.42       5                         --1.95      0.01          Normal             PTPN11 p.Y63C        70

  5     M     7.3        167.5      --2.74       --1.91       6                         --2.58      --0.51        VSD                PTPN11 p.Y63C        63

  6     F     11.3       142        --3.78       --1.57       NA                        --0.22      --0.03        Normal             PTPN11 p.T21         55

  7     F     10.4       165        --2.01       --2.18       4                         --1.64      --0.68        PS, ASD            PTPN11 p.E139D       72

  8     F     6.1        157        --2.45       --1.06       NA                        --0.80      0.82          PS                 PTPN11 p.N308D       70

  9     M     9.8        173        --1.97       --1.74       NA                        --1.11      --0.47        PS                 PTPN11 p.N308D       50

  10    M     6.9        170.5      --2.00       --3.28       5                         --0.92      --0.39        VSD, PDA           SOS1 p.E433K         73

  11    M     6.6        174.5      --1.79       --2.14       4                         --0.13      --0.02        PDA                None                 63

  12    M     7.2        171.5      --2.20       --1.56       4                         --0.36      0.43          Valvar PS          None                 70

  13    M     9.3        179        --2.22       --1.93       4                         --1.66      --0.07        Normal             SOS1 p.R552G         67

  14    M     7.9        NA         --2.61       --3.39       6                         --0.68      --0.11        Valvar PS          KRAS p.I36M          66

  15    F     5.7        158.5      --3.51       --7.23       4                         0.29        --0.10        PA with VSD, PDA   None                 61
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NS, Noonan syndrome; MPH, midparental height; SDS, standard deviation score; IGF-1, insulin-like growth factor 1; IGFBP-3, IGF binding protein 3; rhGH, recombinant human growth hormone; VSD, ventricular septal defect; PS, pulmonary stenosis; ASD, atrial septal defect; RVH, right ventricular hypertrophy; PDA, patent ductus arteriosus; NA, not available; PA, pulmonary atresia.

###### Clinical and endocrinological parameters during rhGH therapy
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  Variable      Baseline      After 1 year   After 2 years   After 3 years   *P*-value
  ------------- ------------- -------------- --------------- --------------- -----------
  CA (yr)       7.97±1.81     8.63±1.32      9.63±1.32       10.63±1.32      NA
  BA (yr)       5.09±2.12     6.31±2.48      8.01±2.19       9.42±2.15       \<0.001
  Height SDS    --2.64±0.64   --2.13±1.08    --1.66±1.24     --1.54±1.24     0.001
  GV (cm/yr)    4.64±0.80     8.57±1.49      6.79±1.26       6.41±1.54       0.003
  IGF-1 SDS     --1.28±1.03   --0.18±0.54    --0.20±0.77     --0.10±0.94     \<0.001
  IGFBP-3 SDS   --0.15±0.40   --0.36±0.25    --0.16±0.21     --0.09±0.34     0.074
  BA/CA ratio   0.62±0.13     0.68±0.15      0.79±0.10       0.86±0.10       0.001

Values are presented as mean±standard deviation.

rhGH, recombinant human growth hormone; CA, chronologic age; BA, bone age; SDS, standard deviation score; GV, growth velocity; IGF-1, insulin-like growth factor 1; IGFBP-3, IGF binding protein 3; NA, not available.
